The impact of neuroimmune alterations in autism spectrum disorder

Frontiers in Psychiatry

Volumn 6, Issue SEP, 2015, Pages

  Gottfried, Carmem ^a   Bambini Junior, Victorio ^a,b   Francis, Fiona ^c,d,e   Riesgo, Rudimar ^a,f   Savino, Wilson ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e INSTITUT DU FER À MOULIN   (France)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Autism; Environmental risk factors; Neuroimmune interactions; Rodent models; Valproic acid

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CELL ADHESION MOLECULE; GAMMA INTERFERON; IMMUNOGLOBULIN G4; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RESVERATROL; SCATTER FACTOR RECEPTOR; SEROTONIN TRANSPORTER; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARCUATE FASCICULUS; ARTICLE; AUTISM; AUTOIMMUNITY; B LYMPHOCYTE; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; CELL ACTIVATION; CELL COMMUNICATION; CELL COUNT; CELL DENSITY; CYTOKINE PRODUCTION; DENDRITIC SPINE; DISEASE SEVERITY; DSM-III; GENETIC ASSOCIATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; INTELLIGENCE QUOTIENT; MACROCEPHALY; MET GENE; MICROGLIA; MOLECULAR INTERACTION; NATURAL KILLER CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PREGNANCY; PROTEIN FUNCTION; PURKINJE CELL; RISK FACTOR; SEX DIFFERENCE; SLC6A4 GENE; T LYMPHOCYTE;

EID: 84944735124     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2015.00121     Document Type: Article

References (178)

1. Ashok AH, Baugh J, Yeragani VK. Paul Eugen Bleuler and the origin of the term schizophrenia. Indian J Psychiatry (2012) 54:95-6. doi:10.4103/0019-5545.94660
2. Kanner L. Autistic disturbances of affective contact. Nervous Child (1943) 2:217-50.
3. Frith U. Asperger and His Syndrome. Cambridge: Cambridge University Press (1991).
4. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature (2015) 523(7560):337-41. doi:10.1038/nature14432
5. Giovannoni G, Miller RF, Heales SJ, Land JM, Harrison MJ, Thompson EJ. Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction. J Neurol Sci (1998) 156:53-8. doi:10.1016/S0022-510X(98)00021-5
6. Goines PE, Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. Neurotoxicol Teratol (2013) 36:67-81. doi:10.1016/j.ntt.2012.07.006
7. DSM-5. Autism Spectrum Disorder. Arlington, VA: American Psychiatric Association (2013).
8. Forrester JV, Xu H, Lambe T, Cornall R. Immune privilege or privileged immunity? Mucosal Immunol (2008) 1:372-81. doi:10.1038/mi.2008.27
9. Riesgo RS, Gottfried C, Becker M. Clinical Approach in Autism: Management and Treatment, In Recent Advances in Autism Spectrum Disorders. Rijeka, Croatia: InTech (2013).
10. Verkhratsky A, Rodriguez JJ, Parpura V. Neuroglia in ageing and disease. Cell Tissue Res (2014) 357:493-503. doi:10.1007/s00441-014-1814-z
11. Weiss LA. Autism genetics: emerging data from genome-wide copy-number and single nucleotide polymorphism scans. Expert Rev Mol Diagn (2009) 9:795-803. doi:10.1586/erm.09.59
12. Wall DP, Esteban FJ, Deluca TF, Huyck M, Monaghan T, Velez de Mendizabal N, et al. Comparative analysis of neurological disorders focuses genome-wide search for autism genes. Genomics (2009) 93:120-9. doi:10.1016/j.ygeno.2008.09.015
13. Matuszek G, Talebizadeh Z. Autism genetic database (AGD): a comprehensive database including autism susceptibility gene-CNVs integrated with known noncoding RNAs and fragile sites. BMC Med Genet (2009) 10:102. doi:10.1186/1471-2350-10-102
14. Miles JH. Autism spectrum disorders-a genetics review. Genet Med (2011) 13:278-94. doi:10.1097/GIM.0b013e3181ff67ba
15. Yu TW, Chahrour MH, Coulter ME, Jiralerspong S, Okamura-Ikeda K, Ataman B, et al. Using whole-exome sequencing to identify inherited causes of autism. Neuron (2013) 77:259-73. doi:10.1016/j.neuron.2012.11.002
16. Moreno-De-Luca D, Sanders SJ, Willsey AJ, Mulle JG, Lowe JK, Geschwind DH, et al. Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. Mol Psychiatry (2012) 18:1090-5. doi:10.1038/mp.2012.138
17. Hsiao EY. Gastrointestinal issues in autism spectrum disorder. Harv Rev Psychiatry (2014) 22:104-11. doi:10.1097/HRP.0000000000000029
18. Jiang YH, Yuen RK, Jin X, Wang M, Chen N, Wu X, et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet (2013) 93:249-63. doi:10.1016/j.ajhg.2013.06.012
19. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics (2004) 113:e472-86. doi:10.1542/peds.113.5.e472
20. Campbell DB, Buie TM, Winter H, Bauman M, Sutcliffe JS, Perrin JM, et al. Distinct genetic risk based on association of MET in families with co-occurring autism and gastrointestinal conditions. Pediatrics (2009) 123:1018-24. doi:10.1542/peds.2008-0819
21. Heuer L, Braunschweig D, Ashwood P, Van de Water J, Campbell DB. Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression. Transl Psychiatry (2011) 1:e48. doi:10.1038/tp.2011.48
22. Campbell DB, D'Oronzio R, Garbett K, Ebert PJ, Mirnics K, Levitt P, et al. Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann Neurol (2007) 62:243-50. doi:10.1002/ana.21180
23. Sakurai T, Reichert J, Hoffman EJ, Cai G, Jones HB, Faham M, et al. A large-scale screen for coding variants in SERT/SLC6A4 in autism spectrum disorders. Autism Res (2008) 1:251-7. doi:10.1002/aur.30
24. Coutinho AM, Sousa I, Martins M, Correia C, Morgadinho T, Bento C, et al. Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum Genet (2007) 121:243-56. doi:10.1007/s00439-006-0301-3
25. Kunze A, Lengacher S, Dirren E, Aebischer P, Magistretti PJ, Renaud P. Astrocyte-neuron co-culture on microchips based on the model of SOD mutation to mimic ALS. Integr Biol (Camb) (2013) 5:964-75. doi:10.1039/c3ib40022k
26. Kim YS, Leventhal BL. Genetic epidemiology and insights into interactive genetic and environmental effects in autism spectrum disorders. Biol Psychiatry (2014) 77:66-74. doi:10.1016/j.biopsych.2014.11.001
27. Lainhart JE, Bigler ED, Bocian M, Coon H, Dinh E, Dawson G, et al. Head circumference and height in autism: a study by the collaborative program of excellence in autism. Am J Med Genet A (2006) 140(21):2257-74. doi:10.1002/ajmg.a.31465
28. Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, et al. Neuron number and size in prefrontal cortex of children with autism. JAMA (2011) 306:2001-10. doi:10.1001/jama.2011.1638
29. Herbert MR, Ziegler DA, Makris N, Filipek PA, Kemper TL, Normandin JJ, et al. Localization of white matter volume increase in autism and developmental language disorder. Ann Neurol (2004) 55(4):530-40. doi:10.1002/ana.20032
30. Hardan AY, Muddasani S, Vemulapalli M, Keshavan MS, Minshew NJ. An MRI study of increased cortical thickness in autism. Am J Psychiatry (2006) 163(7):1290-2. doi:10.1176/ajp.2006.163.7.1290
31. Zikopoulos B, Barbas H. Altered neural connectivity in excitatory and inhibitory cortical circuits in autism. Front Hum Neurosci (2013) 7:609. doi:10.3389/fnhum.2013.00609
32. Casanova MF, Buxhoeveden DP, Switala AE, Roy E. Minicolumnar pathology in autism. Neurology (2002) 58(3):428-32. doi:10.1212/WNL.58.3.428
33. Wegiel J, Kuchna I, Nowicki K, Imaki H, Marchi E, Ma SY, et al. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol (2010) 119:755-70. doi:10.1007/s00401-010-0655-4
34. Simms ML, Kemper TL, Timbie CM, Bauman ML, Blatt GJ. The anterior cingulate cortex in autism: heterogeneity of qualitative and quantitative cytoarchitectonic features suggests possible subgroups. Acta Neuropathol (2009) 118(5):673-84. doi:10.1007/s00401-009-0568-2
35. Oblak AL, Rosene DL, Kemper TL, Bauman ML, Blatt GJ. Altered posterior cingulate cortical cyctoarchitecture, but normal density of neurons and interneurons in the posterior cingulate cortex and fusiform gyrus in autism. Autism Res (2011) 4:200-11. doi:10.1002/aur.188
36. Hutsler JJ, Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res (2009) 1309:83-94. doi:10.1016/j.brainres.2009.09.120
37. Avino TA, Hutsler JJ. Abnormal cell patterning at the cortical gray-white matter boundary in autism spectrum disorders. Brain Res (2010) 1360:138-46. doi:10.1016/j.brainres.2010.08.091
38. Zikopoulos B, Barbas H. Changes in prefrontal axons may disrupt the network in autism. J Neurosci (2010) 30:14595-609. doi:10.1523/JNEUROSCI.2257-10.2010
39. Frazier TW, Hardan AY. A meta-analysis of the corpus callosum in autism. Biol Psychiatry (2009) 66(10):935-41. doi:10.1016/j.biopsych.2009.07.022
40. Casanova MF, El-Baz A, Elnakib A, Switala AE, Williams EL, Williams DL, et al. Quantitative analysis of the shape of the corpus callosum in patients with autism and comparison individuals. Autism (2011) 15:223-38. doi:10.1177/1362361310386506
41. Wolff JJ, Gu H, Gerig G, Elison JT, Styner M, Gouttard S, et al. Differences in white matter fiber tract development present from 6 to 24 months in infants with autism. Am J Psychiatry (2012) 169:589-600. doi:10.1176/appi.ajp.2011.11091447
42. Travers BG, Tromp do PM, Adluru N, Lange N, Destiche D, Ennis C, et al. Atypical development of white matter microstructure of the corpus callosum in males with autism: a longitudinal investigation. Mol Autism (2015) 6:15. doi:10.1186/s13229-015-0001-8
43. Alexander AL, Lee JE, Lazar M, Boudos R, DuBray MB, Oakes TR, et al. Diffusion tensor imaging of the corpus callosum in autism. Neuroimage (2007) 34:61-73. doi:10.1016/j.neuroimage.2006.08.032
44. Thakkar KN, Polli FE, Joseph RM, Tuch DS, Hadjikhani N, Barton JJ, et al. Response monitoring, repetitive behaviour and anterior cingulate abnormalities in autism spectrum disorders (ASD). Brain (2008) 131:2464-78. doi:10.1093/brain/awn099
45. Barnea-Goraly N, Lotspeich LJ, Reiss AL. Similar white matter aberrations in children with autism and their unaffected siblings: a diffusion tensor imaging study using tract-based spatial statistics. Arch Gen Psychiatry (2010) 67:1052-60. doi:10.1001/archgenpsychiatry.2010.123
46. Noriuchi M, Kikuchi Y, Yoshiura T, Kira R, Shigeto H, Hara T, et al. Altered white matter fractional anisotropy and social impairment in children with autism spectrum disorder. Brain Res (2010) 1362:141-9. doi:10.1016/j.brainres.2010.09.051
47. Kana RK, Keller TA, Cherkassky VL, Minshew NJ, Just MA. Atypical frontal-posterior synchronization of theory of mind regions in autism during mental state attribution. Soc Neurosci (2009) 4:135-52. doi:10.1080/17470910802198510
48. Poustka L, Jennen-Steinmetz C, Henze R, Vomstein K, Haffner J, Sieltjes B. Fronto-temporal disconnectivity and symptom severity in children with autism spectrum disorder. World J Biol Psychiatry (2012) 13(4):269-80. doi:10.3109/15622975.2011.591824
49. Koshino H, Kana RK, Keller TA, Cherkassky VL, Minshew NJ, Just MA. fMRI investigation of working memory for faces in autism: visual coding and underconnectivity with frontal areas. Cereb Cortex (2008) 18:289-300. doi:10.1093/cercor/bhm054
50. Just MA, Cherkassky VL, Keller TA, Kana RK, Minshew NJ. Functional and anatomical cortical underconnectivity in autism: evidence from an FMRI study of an executive function task and corpus callosum morphometry. Cereb Cortex (2007) 17:951-61. doi:10.1093/cercor/bhl006
51. Kennedy DP, Courchesne E. Functional abnormalities of the default network during self-and other-reflection in autism. Soc Cogn Affect Neurosci (2008) 3:177-90. doi:10.1093/scan/nsn011
52. Weng SJ, Wiggins JL, Peltier SJ, Carrasco M, Risi S, Lord C, et al. Alterations of resting state functional connectivity in the default network in adolescents with autism spectrum disorders. Brain Res (2013) 1313:202-14. doi:10.1016/j.brainres.2009.11.057
53. Monk CS, Peltier SJ, Wiggins JL, Weng SJ, Carrasco M, Risi S, et al. Abnormalities of intrinsic functional connectivity in autism spectrum disorders. Neuroimage (2009) 47:764-72. doi:10.1016/j.neuroimage.2009.04.069
54. Noonan SK, Haist F, Muller RA. Aberrant functional connectivity in autism: evidence from low-frequency BOLD signal fluctuations. Brain Res (2009) 1262:48-63. doi:10.1016/j.brainres.2008.12.076
55. Kleinhans NM, Richards T, Sterling L, Stegbauer KC, Mahurin R, Johnson LC, et al. Abnormal functional connectivity in autism spectrum disorders during face processing. Brain (2008) 131:1000-12. doi:10.1093/brain/awm334
56. Stouffer M, Golden JA, Francis F. Neuronal migration defects. Neurobiol Dis (in press).
57. Doll CA, Broadie K. Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models. Front Cell Neurosci (2012) 8:30. doi:10.3389/fncel.2014.00030
58. Ning ZY, Zhao DM, Liu HX, Yang JM, Han CX, Cui YL, et al. Altered expression of the prion gene in rat astrocyte and neuron cultures treated with prion peptide 106-126. Cell Mol Neurobiol (2005) 25:1171-83. doi:10.1007/s10571-005-8357-5
59. Estes ML, McAllister AK. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat Rev Neurosci (2015) 16:469-86. doi:10.1038/nrn3978
60. Hazlett HC, Poe MD, Gerig G, Styner M, Chappell C, Smith RG, et al. Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. Arch Gen Psychiatry (2011) 68:467-76. doi:10.1001/archgenpsychiatry.2011.39
61. Kilian S, Brown WS, Hallam BJ, McMahon W, Lu J, Johnson M, et al. Regional callosal morphology in autism and macrocephaly. Dev Neuropsychol (2008) 33:74-99. doi:10.1080/87565640701729821
62. Potts MB, Siu JJ, Price JD, Salinas RD, Cho MJ, Ramos AD, et al. Analysis of Mll1 deficiency identifies neurogenic transcriptional modules and Brn4 as a factor for direct astrocyte-to-neuron reprogramming. Neurosurgery (2014) 75:472-82. doi:10.1227/NEU.0000000000000452
63. Chamak B, Fellous A, Autillo-Touati A, Barbin G, Prochiantz A. Are neuronotrophic neuron-astrocyte interactions regionally specified? Ann N Y Acad Sci (1987) 495:528-36. doi:10.1111/j.1749-6632.1987.tb23698.x
64. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol (2007) 17:103-11. doi:10.1016/j.conb.2007.01.009
65. Pitanga BP, Silva VD, Souza CS, Junqueira HA, Fragomeni BO, Nascimento RP, et al. Assessment of neurotoxicity of monocrotaline, an alkaloid extracted from Crotalaria retusa in astrocyte/neuron co-culture system. Neurotoxicology (2011) 32:776-84. doi:10.1016/j.neuro.2011.07.002
66. Casanova MF. Neuropathological and genetic findings in autism: the significance of a putative minicolumnopathy. Neuroscientist (2006) 12:435-41. doi:10.1177/1073858406290375
67. Zungun C, Yilmaz FM, Tutkun E, Yilmaz H, Uysal S. Assessment of serum S100B and neuron specific enolase levels to evaluate the neurotoxic effects of organic solvent exposure. Clin Toxicol (Phila) (2013) 51:748-51. doi:10.3109/15563650.2013.820831
68. Zhou BY, Liu Y, Kim B, Xiao Y, He JJ. Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes. Mol Cell Neurosci (2004) 27:296-305. doi:10.1016/j.mcn.2004.07.003
69. Cassina P, Pehar M, Vargas MR, Castellanos R, Barbeito AG, Estevez AG, et al. Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem (2005) 93:38-46. doi:10.1111/j.1471-4159.2004.02984.x
70. Aschner M, Bennett BA. Astrocyte and neuron coculturing method. Methods Mol Med (1999) 22:133-44. doi:10.1385/0-89603-612-X:133
71. Yang CZ, Zhao R, Dong Y, Chen XQ, Yu AC. Astrocyte and neuron intone through glutamate. Neurochem Res (2008) 33:2480-6. doi:10.1007/s11064-008-9758-x
72. Schipul SE, Keller TA, Just MA. Inter-regional brain communication and its disturbance in autism. Front Syst Neurosci (2011) 5:10. doi:10.3389/fnsys.2011.00010
73. Travers BG, Adluru N, Ennis C, Tromp do PM, Destiche D, Doran S, et al. Diffusion tensor imaging in autism spectrum disorder: a review. Autism Res (2012) 5:289-313. doi:10.1002/aur.1243
74. Catani M, Jones DK, Daly E, Embiricos N, Deeley Q, Pugliese L, et al. Altered cerebellar feedback projections in Asperger syndrome. Neuroimage (2008) 41:1184-91. doi:10.1016/j.neuroimage.2008.03.041
75. Skefos J, Cummings C, Enzer K, Holiday J, Weed K, Levy E, et al. Regional alterations in purkinje cell density in patients with autism. PLoS One (2014) 9:e81255. doi:10.1371/journal.pone.0081255
76. Rathinam ML, Watts LT, Stark AA, Mahimainathan L, Stewart J, Schenker S, et al. Astrocyte control of fetal cortical neuron glutathione homeostasis: up-regulation by ethanol. J Neurochem (2006) 96:1289-300. doi:10.1111/j.1471-4159.2006.03674.x
77. Blackburn D, Sargsyan S, Monk PN, Shaw PJ. Astrocyte function and role in motor neuron disease: a future therapeutic target? Glia (2009) 57:1251-64. doi:10.1002/glia.20848
78. Amiri M, Hosseinmardi N, Bahrami F, Janahmadi M. Astrocyte-neuron interaction as a mechanism responsible for generation of neural synchrony: a study based on modeling and experiments. J Comput Neurosci (2013) 34:489-504. doi:10.1007/s10827-012-0432-6
79. Liu QY, Schaffner AE, Chang YH, Barker JL. Astrocyte-conditioned saline supports embryonic rat hippocampal neuron differentiation in short-term cultures. J Neurosci Methods (1998) 86:71-7. doi:10.1016/S0165-0270(98)00146-0
80. Agarwal A, Bergles DE. Astrocyte morphology is controlled by neuron-derived FGF. Neuron (2014) 83:255-7. doi:10.1016/j.neuron.2014.07.005
81. Bradstreet JJ, Pacini S, Ruggiero M. A new methodology of viewing extra-axial fluid and cortical abnormalities in children with autism via transcranial ultrasonography. Front Hum Neurosci (2014) 7:934. doi:10.3389/fnhum.2013.00934
82. Marchetti B. Cross-talk signals in the CNS: role of neurotrophic and hormonal factors, adhesion molecules and intercellular signaling agents in luteinizing hormone-releasing hormone (LHRH)-astroglial interactive network. Front Biosci (1997) 2:d88-125.
83. Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Results Probl Cell Differ (2009) 51:197-216. doi:10.1007/400_2009_6
84. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev (1996) 17:64-102. doi:10.1210/edrv-17-1-64
85. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun (2011) 26:383-92. doi:10.1016/j.bbi.2011.08.007
86. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C. Cytokine signals propagate through the brain. Mol Psychiatry (2000) 5:604-15. doi:10.1038/sj.mp.4000813
87. Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. Mast cells, brain inflammation and autism. Eur J Pharmacol (2015). doi:10.1016/j.ejphar.2015.03.086
88. Stubbs EG, Crawford ML. Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr (1977) 7:49-55. doi:10.1007/BF01531114
89. Wills S, Cabanlit M, Bennett J, Ashwood P, Amaral D, Van de Water J. Autoantibodies in autism spectrum disorders (ASD). Ann N Y Acad Sci (2007) 1107:79-91. doi:10.1196/annals.1381.009
90. Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA, et al. Maternal antibrain antibodies in autism. Brain Behav Immun (2007) 21:351-7. doi:10.1016/j.bbi.2006.08.005
91. Braunschweig D, Van de Water J. Maternal autoantibodies in autism. Arch Neurol (2012) 69:693-9. doi:10.1001/archneurol.2011.2506
92. Gupta S, Samra D, Agrawal S. Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin. J Clin Immunol (2010) 30(Suppl 1):S90-6. doi:10.1007/s10875-010-9402-9
93. Mostafa GA, El-Sherif DF, Al-Ayadhi LY. Systemic auto-antibodies in children with autism. J Neuroimmunol (2014) 272:94-8. doi:10.1016/j.jneuroim.2014.04.011
94. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun (2011) 25:40-5. doi:10.1016/j.bbi.2010.08.003
95. Suzuki K, Matsuzaki H, Iwata K, Kameno Y, Shimmura C, Kawai S, et al. Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS One (2011) 6:e20470. doi:10.1371/journal.pone.0020470
96. Emanuele E, Orsi P, Boso M, Broglia D, Brondino N, Barale F, et al. Low-grade endotoxemia in patients with severe autism. Neurosci Lett (2010) 471:162-5. doi:10.1016/j.neulet.2010.01.033
97. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol (2001) 120:170-9. doi:10.1016/S0165-5728(01)00421-0
98. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun (2009) 24(1):64-71. doi:10.1016/j.bbi.2009.08.001
99. Malik M, Sheikh AM, Wen G, Spivack W, Brown WT, Li X. Expression of inflammatory cytokines, Bcl2 and cathepsin D are altered in lymphoblasts of autistic subjects. Immunobiology (2011) 216:80-5. doi:10.1016/j.imbio.2010.03.001
100. Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, et al. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflammation (2011) 8:52. doi:10.1186/1742-2094-8-52
101. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol (2005) 57:67-81. doi:10.1002/ana.20315
102. Xu N, Li X, Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators Inflamm (2015) 2015:531518. doi:10.1155/2015/531518
103. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol (2009) 207(1-2):111-6. doi:10.1016/j.jneuroim.2008.12.002
104. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology (2002) 45(1):1-6. doi:10.1159/000048665
105. Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen RL, Croen LA, et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol (2008) 204:149-53. doi:10.1016/j.jneuroim.2008.07.006
106. Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, et al. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry (2007) 31:187-90. doi:10.1016/j.pnpbp.2006.08.020
107. Brimberg L, Sadiq A, Gregersen PK, Diamond B. Brain-reactive IgG correlates with autoimmunity in mothers of a child with an autism spectrum disorder. Mol Psychiatry (2013) 18:1171-7. doi:10.1038/mp.2013.101
108. Parker-Athill EC, Tan J. Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway. Neurosignals (2010) 18:113-28. doi:10.1159/000319828
109. Mazur-Kolecka B, Cohen IL, Gonzalez M, Jenkins EC, Kaczmarski W, Brown WT, et al. Autoantibodies against neuronal progenitors in sera from children with autism. Brain Dev (2014) 36:322-9. doi:10.1016/j.braindev.2013.04.015
110. Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc Natl Acad Sci U S A (2012) 109:12776-81. doi:10.1073/pnas.1202556109
111. Schwartzer JJ, Careaga M, Onore CE, Rushakoff JA, Berman RF, Ashwood P. Maternal immune activation and strain specific interactions in the development of autism-like behaviors in mice. Transl Psychiatry (2013) 3:e240. doi:10.1038/tp.2013.16
112. Lucchina L, Depino AM. Altered peripheral and central inflammatory responses in a mouse model of autism. Autism Res (2014) 7:273-89. doi:10.1002/aur.1338
113. Enstrom AM, Lit L, Onore CE, Gregg JP, Hansen RL, Pessah IN, et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun (2009) 23:124-33. doi:10.1016/j.bbi.2008.08.001
114. Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med (2011) 17:389-94. doi:10.1016/j.molmed.2011.03.001
115. Atladottir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics (2009) 124:687-94. doi:10.1542/peds.2008-2445
116. Warrington AE, Bieber AJ, Van Keulen V, Ciric B, Pease LR, Rodriguez M. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol (2004) 63:461-73.
117. Baslow MH, Dyakin VV, Nowak KL, Hungund BL, Guilfoyle DN. 2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia. J Mol Neurosci (2005) 26:1-15. doi:10.1385/JMN:26:1:001
118. Enstrom AM, Van de Water JA, Ashwood P. Autoimmunity in autism. Curr Opin Investig Drugs (2009) 10:463-73.
119. Lyall K, Ashwood P, Van de Water J, Hertz-Picciotto I. Maternal immune-mediated conditions, autism spectrum disorders, and developmental delay. J Autism Dev Disord (2013) 44:1546-55. doi:10.1007/s10803-013-2017-2
120. Sweeten TL, Posey DJ, McDougle CJ. High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry (2003) 160:1691-3. doi:10.1176/appi.ajp.160.9.1691
121. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun (2009) 24:64-71. doi:10.1016/j.bbi.2009.08.001
122. Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol (2007) 36:361-5. doi:10.1016/j.pediatrneurol.2007.01.012
123. Sordet O, Rebe C, Plenchette S, Zermati Y, Hermine O, Vainchenker W, et al. Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood (2002) 100:4446-53. doi:10.1182/blood-2002-06-1778
124. Siniscalco D, Sapone A, Giordano C, Cirillo A, de Novellis V, de Magistris L, et al. The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients. J Autism Dev Disord (2012) 42:1403-10. doi:10.1007/s10803-011-1373-z
125. Goncharova ND. Stress responsiveness of the hypothalamic-pituitary-adrenal axis: age-related features of the vasopressinergic regulation. Front Endocrinol (2013) 4:26. doi:10.3389/fendo.2013.00026
126. Tostes MH, Teixeira HC, Gattaz WF, Brandao MA, Raposo NR. Altered neurotrophin, neuropeptide, cytokines and nitric oxide levels in autism. Pharmacopsychiatry (2012) 45:241-3. doi:10.1055/s-0032-1301914
127. Sweeten TL, Posey DJ, Shankar S, McDougle CJ. High nitric oxide production in autistic disorder: a possible role for interferon-gamma. Biol Psychiatry (2004) 55:434-7. doi:10.1016/j.biopsych.2003.09.001
128. Ghanizadeh A, Akhondzadeh S, Hormozi M, Makarem A, Abotorabi-Zarchi M, Firoozabadi A. Glutathione-related factors and oxidative stress in autism, a review. Curr Med Chem (2012) 19:4000-5. doi:10.2174/092986712802002572
129. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med (2012) 52:2128-41. doi:10.1016/j.freeradbiomed.2012.03.011
130. Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A. Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol Trace Elem Res (2010) 143:58-65. doi:10.1007/s12011-010-8840-9
131. Schneider T, Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology (2005) 30:80-9. doi:10.1038/sj.npp.1300518
132. Rao SP, Sikdar SK. Acute treatment with 17beta-estradiol attenuates astrocyte-astrocyte and astrocyte-neuron communication. Glia (2007) 55:1680-9. doi:10.1002/glia.20564
133. Bilbo SD, Schwarz JM. The immune system and developmental programming of brain and behavior. Front Neuroendocrinol (2012) 33:267-86. doi:10.1016/j.yfrne.2012.08.006
134. Sierra A, Tremblay ME, Wake H. Never-resting microglia: physiological roles in the healthy brain and pathological implications. Front Cell Neurosci (2014) 8:240. doi:10.3389/fncel.2014.00240
135. Sierra A, Beccari S, Diaz-Aparicio I, Encinas JM, Comeau S, Tremblay ME. Surveillance, phagocytosis, and inflammation: how never-resting microglia influence adult hippocampal neurogenesis. Neural Plast (2014) 2014:610343. doi:10.1155/2014/610343
136. Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry (2010) 68:368-76. doi:10.1016/j.biopsych.2010.05.024
137. Tetreault NA, Hakeem AY, Jiang S, Williams BA, Allman E, Wold BJ, et al. Microglia in the cerebral cortex in autism. J Autism Dev Disord (2012) 42:2569-84. doi:10.1007/s10803-012-1513-0
138. Patel AS, Zalcman SS. Interleukin-2 treatment induces an acquired behavioral response pattern (repetitive stereotyped movements) mediated by dopamine D1 and D2 receptors. Int Neuropsychiatr Dis J (2014) 2:175-85. doi:10.9734/INDJ/2014/7284
139. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs (2000) 9:497-514. doi:10.1517/13543784.9.3.497
140. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J (1991) 5:2567-74.
141. Heaney ML, Golde DW. Soluble cytokine receptors. Blood (1996) 87:847-57.
142. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev (2009) 28:305-16. doi:10.1007/s10555-009-9198-3
143. Brighenti M. MicroRNA and MET in lung cancer. Ann Transl Med (2015) 3:68. doi:10.3978/j.issn.2305-5839.2015.01.26
144. Wang L, He L, Zhang R, Liu X, Ren Y, Liu Z, et al. Regulation of T lymphocyte activation by microRNA-21. Mol Immunol (2014) 59:163-71. doi:10.1016/j.molimm.2014.02.004
145. Mellios N, Sur M. The emerging role of microRNAs in schizophrenia and autism spectrum disorders. Front Psychiatry (2012) 3:39. doi:10.3389/fpsyt.2012.00039
146. Mundalil Vasu M, Anitha A, Thanseem I, Suzuki K, Yamada K, Takahashi T, et al. Serum microRNA profiles in children with autism. Mol Autism (2014) 5:40. doi:10.1186/2040-2392-5-40
147. Olde Loohuis NF, Kole K, Glennon JC, Karel P, Van der Borg G, Van Gemert Y, et al. Elevated microRNA-181c and microRNA-30d levels in the enlarged amygdala of the valproic acid rat model of autism. Neurobiol Dis (2015) 80:42-53. doi:10.1016/j.nbd.2015.05.006
148. Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol (2006) 173:126-34. doi:10.1016/j.jneuroim.2005.12.007
149. Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J Clin Immunol (2004) 24:664-73. doi:10.1007/s10875-004-6241-6
150. Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K, et al. Mast cell activation and autism. Biochim Biophys Acta (2012) 1822:34-41. doi:10.1016/j.bbadis.2010.12.017
151. Enstrom A, Krakowiak P, Onore C, Pessah IN, Hertz-Picciotto I, Hansen RL, et al. Increased IgG4 levels in children with autism disorder. Brain Behav Immun (2009) 23:389-95. doi:10.1016/j.bbi.2008.12.005
152. Coisne C, Dehouck L, Faveeuw C, Delplace Y, Miller F, Landry C, et al. Mouse syngenic in vitro blood-brain barrier model: a new tool to examine inflammatory events in cerebral endothelium. Lab Invest (2005) 85:734-46. doi:10.1038/labinvest.3700281
153. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol (2008) 9:137-45. doi:10.1038/ni1551
154. Bambini-Junior V, Zanatta G, Della Flora Nunes G, Mueller de Melo G, Michels M, Fontes-Dutra M, et al. Resveratrol prevents social deficits in animal model of autism induced by valproic acid. Neurosci Lett (2014) 583:176-81. doi:10.1016/j.neulet.2014.09.039
155. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle (2008) 7:1020-35. doi:10.4161/cc.7.8.5740
156. Dong W, Li N, Gao D, Zhen H, Zhang X, Li F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J Vasc Surg (2008) 48(3):709-14. doi:10.1016/j.jvs.2008.04.007
157. Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci (2002) 71(6):655-65. doi:10.1016/S0024-3205(02)01691-0
158. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 6:e19881. doi:10.1371/journal.pone.0019881
159. Schneider T, Roman A, Basta-Kaim A, Kubera M, Budziszewska B, Schneider K, et al. Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology (2008) 33:728-40. doi:10.1016/j.psyneuen.2008.02.011
160. Bambini-Junior V, Nunes GD, Schneider T, Gottfried C. Comment on "oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring". Science (2014) 346:176. doi:10.1126/science.1255679
161. Bambini-Junior V, Rodrigues L, Behr GA, Moreira JC, Riesgo R, Gottfried C. Animal model of autism induced by prenatal exposure to valproate: behavioral changes and liver parameters. Brain Res (2011) 1408:8-16. doi:10.1016/j.brainres.2011.06.015
162. Petro TM. Regulatory role of resveratrol on Th17 in autoimmune disease. Int Immunopharmacol (2011) 11:310-8. doi:10.1016/j.intimp.2010.07.011
163. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, Nagarkatti P. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol (2007) 72:1508-21. doi:10.1124/mol.107.038984
164. Sakic B, Szechtman H, Denburg JA. Neurobehavioral alterations in autoimmune mice. Neurosci Biobehav Rev (1997) 21:327-40. doi:10.1016/S0149-7634(96)00018-8
165. Hornig M, Weissenbock H, Horscroft N, Lipkin WI. An infection-based model of neurodevelopmental damage. Proc Natl Acad Sci U S A (1999) 96:12102-7. doi:10.1073/pnas.96.21.12102
166. Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci (2003) 23:297-302.
167. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci (2007) 27:10695-702. doi:10.1523/JNEUROSCI.2178-07.2007
168. Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: a pregnant dam mouse model. J Neuroimmunol (2009) 211:39-48. doi:10.1016/j.jneuroim.2009.03.011
169. Willette AA, Lubach GR, Knickmeyer RC, Short SJ, Styner M, Gilmore JH, et al. Brain enlargement and increased behavioral and cytokine reactivity in infant monkeys following acute prenatal endotoxemia. Behav Brain Res (2011) 219:108-15. doi:10.1016/j.bbr.2010.12.023
170. Malkova NV, Yu CZ, Hsiao EY, Moore MJ, Patterson PH. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun (2012) 26:607-16. doi:10.1016/j.bbi.2012.01.011
171. Bauman MD, Iosif AM, Smith SE, Bregere C, Amaral DG, Patterson PH. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biol Psychiatry (2014) 75:332-41. doi:10.1016/j.biopsych.2013.06.025
172. Camacho J, Jones K, Miller E, Ariza J, Noctor S, Van de Water J, et al. Embryonic intraventricular exposure to autism-specific maternal autoantibodies produces alterations in autistic-like stereotypical behaviors in offspring mice. Behav Brain Res (2014) 266:46-51. doi:10.1016/j.bbr.2014.02.045
173. Onore CE, Schwartzer JJ, Careaga M, Berman RF, Ashwood P. Maternal immune activation leads to activated inflammatory macrophages in offspring. Brain Behav Immun (2014) 38:220-6. doi:10.1016/j.bbi.2014.02.007
174. Xuan IC, Hampson DR. Gender-dependent effects of maternal immune activation on the behavior of mouse offspring. PLoS One (2014) 9:e104433. doi:10.1371/journal.pone.0104433
175. Hwang SR, Kim CY, Shin KM, Jo JH, Kim HA, Heo Y. Altered expression levels of neurodevelopmental proteins in fetal brains of BTBR T+tf/J mice with autism-like behavioral characteristics. J Toxicol Environ Health A (2015) 78:516-23. doi:10.1080/15287394.2015.1010466
176. Kim SN, Jo GH, Kim HA, Heo Y. Aberrant IgG isotype generation in mice with abnormal behaviors. J Immunotoxicol (2015):1-5. doi:10.3109/1547691X.2015.1014581
177. Luan R, Cheng H, Li L, Zhao Q, Liu H, Wu Z, et al. Maternal lipopolysaccharide exposure promotes immunological functional changes in adult offspring CD4 T cells. Am J Reprod Immunol (2015) 73:522-35. doi:10.1111/aji.12364
178. Hsiao EY, Patterson PH. Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav Immun (2011) 25:604-15. doi:10.1016/j.bbi.2010.12.017